MESA, ARIZONA / ACCESS Newswire / October 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a developer of artificial intelligence-powered preventive health technology, today emphasized the urgent human need driving each vertical of its AI platform - underscoring the global lives lost and affected every year to conditions that may be better managed through earlier detection and awareness. Skin Health Over 60,000 people die from melanoma and other skin cancers each year. ...

Core Viewpoint - Xcelerate, Inc. has divested its majority interest in the ESN Group of companies to Noble Labs Holdings, LLC in an all-cash transaction to refocus on its core mission of implementing AI-aided medical technology and virtual healthcare in Africa through its subsidiary AfiyaSasa Africa, LLC [1] Company Summary - The sale includes the ESN Group, Inc. and California Skin Research, Inc. [1] - Noble Labs Holdings, LLC had previously provided funding and marketing support to the ESN Group, indicating a strategic partnership [1] - The decision to divest was made to realign the company's focus on its original mission [1]

Core Insights - Nexalin Technology Inc. (NASDAQ:NXL) experienced a significant stock price increase of 69.47%, reaching $1.59, with a trading volume of 167.9 million shares compared to the average of 972.2 thousand shares [1][7]. Clinical Data and Findings - The company published positive clinical data indicating that its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS technology improves cognitive performance and enhances brain network connectivity in patients with mild Alzheimer's disease (AD) [2]. - Patients using Nexalin's Gen-2 SYNC 40-Hz DIFS device showed significant improvements in Mini-Mental State Examination (MMSE) scores and Montreal Cognitive Assessment (MoCA) scores compared to baseline, with statistical significance (P = .001 and .03, respectively) [3]. - Resting-state functional MRI (fMRI) demonstrated enhanced functional connectivity (FC) between the hippocampus and critical cortical regions, which are essential for memory and executive function, with significant increases observed across broader cognitive networks [4]. Correlation and Safety - Increased connectivity between the hippocampus and middle cingulate gyrus correlated with improvements on the Boston Naming Test (r = 0.65, FDR-adjusted P = .008), indicating a link between brain network modulation and functional outcomes [5]. - No adverse events were reported during the treatment period, highlighting the safety and tolerability of Nexalin's DIFS technology [5]. Regulatory Approvals and Strategy - Nexalin's Gen-2 SYNC 15 mA DIFS device is already approved in China for treating depression and insomnia, and it has approvals in Brazil and Oman for anxiety, depression, and insomnia [6]. - The new Alzheimer's data supports the company's strategy to expand treatment indications with various international regulatory agencies, including the FDA in the United States [6].

Core Insights - Tilray Brands (TLRY) is set to report its first-quarter fiscal 2026 results on October 9, 2025, before market opening [1] - The company reported fourth-quarter fiscal 2025 adjusted earnings of 2 cents per share, exceeding the Zacks Consensus Estimate by 166.67% [1] - TLRY has beaten earnings estimates in two of the last four quarters and missed in the other two [1] Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues in the upcoming quarter is $206.8 million, indicating a 3.4% increase from the previous year [2] - The loss per share estimate is set at 3 cents, reflecting a 25% year-over-year increase [2] - Estimates for loss per share have remained unchanged at 3 cents over the past 30 days [3] Factors Influencing Performance - **Cannabis Segment**: In the fourth quarter of fiscal 2025, cannabis net revenues declined year-over-year due to a pause in vape and infused pre-roll categories and delays in international medical cannabis permits. However, international cannabis revenues reached a record high of $22.4 million, with Germany showing 134% growth [4] - **Tilray Medical**: The division introduced three new medical cannabis flower varieties in Italy, becoming the first authorized company to import and distribute its products there. A strategic partnership with Molteni aims to enhance the availability of Tilray Medical cannabis extracts in Italy, expected to boost top-line growth [5] Segment Performance Expectations - **Beverages**: The Beverages segment is anticipated to see a revenue decline due to SKU rationalization under Project 420. However, the Breckenridge Distillery brand is expected to show resilience in the bourbon sector [8][10] - **Wellness**: The Wellness segment is projected to experience a year-over-year revenue surge, driven by the growth of Manitoba Harvest Hemp Hearts and new product innovations [11] - **Distribution**: Distribution revenues, primarily from Tilray Pharma, are expected to grow due to changes in product mix [12] Earnings Outlook - Tilray Brands has an Earnings ESP of 0.00%, indicating no expected earnings surprise for the upcoming report [13] - The company currently holds a Zacks Rank of 3, suggesting a neutral outlook [13]

Core Viewpoint - Senzime AB has announced the launch of EMGINETM, a proprietary software suite for its next-generation TetraGraph® platform, which will be unveiled at the ANESTHESIOLOGY® 2025 conference [1] Group 1 - The new technology, EMGINETM, is part of Senzime's ongoing innovation in the medical technology sector [1] - The unveiling of EMGINETM is scheduled for the ANESTHESIOLOGY® 2025 conference, taking place from October 11-13 in San Antonio, Texas, USA [1]

Core Points - Globalink Investment Inc. has extended the deadline to complete its initial business combination from October 9, 2025, to November 9, 2025, by depositing $0.15 per public share, totaling $10,890.15 into its trust account [1] - This extension marks the twenty-eighth extension since the company's initial public offering on December 9, 2021, and the fifth of up to six extensions allowed under its governing documents [1] Company Overview - Globalink is a special purpose acquisition company (SPAC) formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [2] - The company has no restrictions on the industry or geographic region for potential targets but intends to focus on the medical technology and green energy sectors in North America, Europe, Southeast Asia, and Asia (excluding China, Hong Kong, and Macau) [2]

Core Insights - Medical Care Technologies Inc. is implementing a strategic plan to separate its AI health applications into two distinct divisions [1] - The first division will focus on clinical validation and regulatory approval, while the second will cater to consumer and research-based wellness monitoring [1] - The company's platform utilizes deep learning, computer vision, and biometric analytics to integrate various diagnostic and predictive modules [1] Company Strategy - The separation of AI health applications aims to enhance focus and efficiency in both clinical and consumer markets [1] - By creating distinct divisions, the company seeks to streamline processes for regulatory compliance and consumer engagement [1] Technology and Innovation - The proprietary platform of Medical Care Technologies Inc. is designed to leverage advanced technologies such as deep learning and computer vision [1] - The integration of multiple diagnostic and predictive modules positions the company as an innovator in AI-driven preventive healthcare [1]

Core Insights - Dova Health Intelligence Inc. collaborates with Mayo Clinic to develop and validate DovaVision UC Mayo Endoscopic Score (MES), an AI tool for scoring ulcerative colitis disease activity from colonoscopy videos [1][3] Company Overview - Dova Health Intelligence specializes in AI-driven solutions for gastrointestinal disease assessment, focusing on improving diagnosis, monitoring, and treatment decision-making [6] - The company's flagship technologies include DovaVision UC MES for ulcerative colitis assessment, DovaVision BE for Barrett's esophagus, and DovaSound for intestinal ultrasound image capture [6] Collaboration Details - The partnership aims to refine DovaVision UC MES for integration into gastroenterology workflows and prepare for FDA regulatory clearance [3][4] - Mayo Clinic's expertise in inflammatory bowel disease (IBD) care and research will enhance the validation process of DovaVision UC MES [4][5] Technology Impact - DovaVision UC MES utilizes computer vision and deep learning to standardize scoring and reduce variability in mucosal healing assessments, which is crucial for IBD management [2] - The collaboration is expected to set new standards in digital assessment and accelerate innovation in clinical trial design and patient care [5]

Core Insights - Catalyst MedTech has launched a new initiative called the Connect program aimed at enhancing patient care by facilitating collaboration among stakeholders [1] - The Connect program utilizes Catalyst's dual business structure, which includes Equipment Solutions and Clinical Solutions, to create customizable pathways for improving access to diagnostic imaging and treatment [1] Company Overview - Catalyst MedTech focuses on advancing patient care through innovative solutions that integrate equipment and clinical services [1] - The company aims to expand access to essential medical services, particularly in the areas of diagnostic imaging and treatment [1]

Core Insights - The Toronto Heart Centre is set to conduct a comparative evaluation of CardioYield™ to enhance Holter ECG analysis and reporting efficiency [1] - The study aims to measure time savings, throughput improvements, and analysis quality when using CardioYield™ compared to current industry-standard software [1] Clinical Workflow Impact - The evaluation will focus on the impact of CardioYield™ on clinical workflows, specifically in terms of efficiency and effectiveness in ECG analysis [1] - Key metrics for assessment include time savings and improvements in throughput and analysis quality [1]